FdaApplication
NDA 019787
Identifiers
- fda_app_no: NDA019787
Properties
| Property | Value |
|---|---|
| applicant_name | VIATRIS SPECIALTY LLC |
| application_type | NDA |
| approval_date | 1992-07-31 |
Revenue by product
NORVASC
| Period | Revenue |
|---|---|
| Q2 2026 | $200.2M |
| Q1 2026 | $210.0M |
| Q4 2025 | $175.2M |
| Q3 2025 | $179.7M |
| Q2 2025 | $182.7M |
| Q1 2025 | $172.3M |
| Q4 2024 | $166.2M |
| Q3 2024 | $168.9M |
| Q2 2024 | $161.9M |
| Q1 2024 | $176.3M |
| Q4 2023 | $171.8M |
| Q3 2023 | $175.5M |
| Q2 2023 | $182.4M |
| Q1 2023 | $202.7M |
| Q4 2022 | $175.0M |
| Q3 2022 | $189.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NORVASC | AMLODIPINE BESYLATE | EQ 10MG BASE | TABLET;ORAL |
| NORVASC | AMLODIPINE BESYLATE | EQ 5MG BASE | TABLET;ORAL |
| NORVASC | AMLODIPINE BESYLATE | EQ 2.5MG BASE | TABLET;ORAL |
3 products